Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002625045 | SCV003519719 | uncertain significance | Cutis laxa, autosomal recessive, type 1B | 2022-05-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with EFEMP2-related conditions. This variant is present in population databases (rs751149606, gnomAD 0.02%). This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 106 of the EFEMP2 protein (p.Pro106Thr). |
Ambry Genetics | RCV004992545 | SCV005572091 | uncertain significance | Cardiovascular phenotype | 2024-08-28 | criteria provided, single submitter | clinical testing | The p.P106T variant (also known as c.316C>A), located in coding exon 3 of the EFEMP2 gene, results from a C to A substitution at nucleotide position 316. The proline at codon 106 is replaced by threonine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |